Molecular Biomarkers/Non-invasive Diagnosis Of Colon CA

Information

  • Research Project
  • 6444239
  • ApplicationId
    6444239
  • Core Project Number
    R43CA086699
  • Full Project Number
    1R43CA086699-01A2
  • Serial Number
    86699
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/22/2002 - 22 years ago
  • Project End Date
    12/31/2003 - 21 years ago
  • Program Officer Name
    DASCHNER, PHILLIP J.
  • Budget Start Date
    7/22/2002 - 22 years ago
  • Budget End Date
    12/31/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    7/22/2002 - 22 years ago

Molecular Biomarkers/Non-invasive Diagnosis Of Colon CA

DESCRIPTION (provided by applicant): Colorectal cancer is a leading cause of death in the United States. There is very strong evidence that screening for this disease can reduce colorectal cancer mortality. Present screening methods include fecal occult blood testing (FOBT) and endoscopy, which can detect some early colon cancers and large polyps. However, FOBT screening suffers from large numbers of false positive and negative results. Whereas periodic sigmoidoscopy can significantly reduce mortality from colon cancer, currently only about 7 percent of eligible persons receive sigmoidoscopic screening. The goal of this project is to develop novel non-invasive molecular biomarkers for the diagnosis of human colon cancer based on multiplex PCR amplification of mRNA coding for eicosanoid-metabolizing enzymes in fecal matter, using quantitative PCR methodology. The expression of the target genes will be normalized relative to an epithelial and a leukocyte cell marker, cytokeratine-19 and leukocyte , respectively. In preliminary studies, significant levels of Cox-2 mRNA were found in fecal matter of older Min mice, with little or no Cox-2 mRNA in the fecal matter of young Min mice or control wild type mice. Specific aims for Phase I research include: development and optimization of real-time multiplex RT-PCR conditions suitable for isolation and quantification of selected mRNA species in human fecal matter, and preliminary studies on the utility of quantitative multiplex RT-PCR for the diagnosis of human colon cancer using coded fecal samples obtained from normal individuals and from colon cancer patients prior to surgical removal of the colon. PROPOSED COMMERCIAL APPLICATIONS: There is a great need, and a very larger market for a reliable non-invasive diagnostic screening test for human colon cancer. The multiplex RT-PCR quantification of fecal mRNAs which encode selected proteins in eicosanoid metabolism and inflammatory pathways is expected to provide a sensitive and reliable method for the differential diagnosis of human colon cancer.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    96484
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    393
  • Ed Inst. Type
  • Funding ICs
    NCI:96484\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OXFORD BIOMEDICAL RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    ROCHESTER HILLS
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    48309
  • Organization District
    UNITED STATES